VivoSeq
Other

Abuse Potential

0

Pipeline Programs↗

1

Active Trials↗

20

Companies Involved↗

Abuse Potential is an early-stage landscape with 0 programs across 20 companies. The most active players are Tris Pharma, Inc., Viatris Specialty LLC, Pfizer.

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

91/100

Attrition Rate

9/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

T

Tris Pharma, Inc.

0 programs

PreclinicalV

Viatris Specialty LLC

0 programs

PreclinicalPfizer logo

Pfizer

0 programs

PreclinicalEisai logo

Eisai

0 programs

PreclinicalP

Pain Therapeutics

0 programs

PreclinicalJohnson & Johnson logo

Johnson & Johnson

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

46

clinical trials

Completed40 · 87%
Terminated3 · 7%
Withdrawn1 · 2%
Recruiting1 · 2%
Unknown status1 · 2%

Clinical Trials

Trial Activity

46 trials

Low-dose Buccal Buprenorphine: Relative Abuse Potential and Analgesia
Recruiting·VVanderbilt University Medical Center·Phase 4·NCT05988710·120 enrolled
Study to Evaluate the Relative Abuse Potential of Almorexant in Recreational Drug Users
Completed·MMidnight Pharma, LLC·Phase 1·NCT01987739·42 enrolled
A Study to Determine the Abuse Potential of Single Oral Doses of Lemborexant Compared to Zolpidem, Suvorexant and Placebo in Healthy, Non-Dependent, Recreational Sedative Users
Completed·Eisai logoEisai·Phase 1·NCT03158025·39 enrolled
Assessment of Abuse Potential of Cebranopadol in Humans
Completed·TTris Pharma, Inc.·Phase 1·NCT05256108·38 enrolled
Oral Abuse Potential Study of Nalbuphine
Completed·TTrevi Therapeutics·Phase 1·NCT04018664·56 enrolled
A Study of the Abuse Potential of Dronabinol in Recreational Cannabinoid Users
Completed·IINSYS Therapeutics Inc·Phase 1·NCT02094599·43 enrolled
Nasal Human Abuse Potential of PTI-821
Completed·PPain Therapeutics·Phase 1·NCT03475862·38 enrolled
Study Evaluating the Abuse Potential of NEURONTIN® in Healthy Non-drug Dependent, Recreational Opioid Users
Completed·VViatris Specialty LLC·Phase 4·NCT05319756·54 enrolled
To Evaluate the Relative Abuse Potential of Hydrocodone Bitartrate and Acetaminophen
Completed·Sun Pharma Advanced Research Company Limited logoSun Pharma Advanced Research Company Limited·Phase 1·NCT03567941·32 enrolled
Study to Evaluate the Abuse Potential of ACT-541468 in Healthy Recreational Drug Users
Completed·Idorsia Pharmaceuticals Ltd. logoIdorsia Pharmaceuticals Ltd.·Phase 1·NCT03657355·63 enrolled
A Study to Determine the Abuse Potential of Seltorexant Compared to Suvorexant and Zolpidem
Completed·Johnson & Johnson logoJohnson & Johnson·Phase 1·NCT05106153·127 enrolled
Abuse Potential of HORIZANT With and Without Oxycodone in Healthy, Nondependent Recreational Opioid Users
Completed·AArbor Pharmaceuticals, Inc.·Phase 4·NCT06247488·110 enrolled
A Study to Evaluate the Abuse Potential of EB-1020 Immediate-Release in Healthy Recreational Stimulant Users
Completed·NNeurovance, Inc.·Phase 1·NCT02144415·80 enrolled
Evaluating the Abuse Potential of NEURONTIN® When Taken Orally in Healthy Non-drug Dependent Participants With Sedative Drug Abuse Experience
Completed·VViatris Specialty LLC·Phase 4·NCT04570436·52 enrolled
Abuse Potential Study of PF-00345439
Completed·PPain Therapeutics·Phase 1·NCT01986283·67 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)